<i>Limosilactobacillus reuteri</i> CCFM1132 modulates gut microbiota and alleviates hyperuricemia: a randomized, double-blind, placebo-controlled trial

This randomized, double-blind, placebo-controlled trial evaluated the uric acid (UA)-lowering effect of <em>Limosilactobacillus reuteri</em><em> </em>CCFM1132 in young males with hyperuricemia. Participants received 1×10¹⁰ CFU of <em>L. reuteri</em> CCFM1132 (n=34) or placebo (n=31) daily for 8 weeks. After the intervention, serum UA concentration significantly decreased, along with a reduction in xanthine oxidase (XOD) activity compared to the placebo group (<em>P &lt; </em>0.01). Indicators of liver (aspartate transaminase and alanine transaminase) and renal (urea and creatinine) functions improved. Short-chain fatty acid (SCFA) concentrations significantly increased, with an upregulated abundance of SCFA producers (<em>Fusicatenibacter</em>, <em>Ruminococcaceae UCG_014</em>, and <em>Ruminococcus 1</em>) in the gut. Additionally, correlation analysis revealed that concentrations of SCFAs, particularly acetate and butyrate, were strongly negatively correlated with UA concentration and XOD activity. These findings suggest that <em>L. reuteri</em> CCFM1132 relieves hyperuricemia by enhancing the abundance of SCFA producers in the gut to promote SCFA production and by suppressing XOD activity. This study provides a valuable reference for developing new treatments for hyperuricemia